TRUE — Treatment.com AI Share Price
Last trade - 00:00- CA$30.58m
- CA$28.41m
- CA$0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.34 | ||
| Price to Tang. Book | 13.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2,782.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -380.65% | ||
| Return on Equity | -500.92% | ||
| Operating Margin | -79419.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | 0.01 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Treatment.com AI Inc., through its wholly owned subsidiary, Treatment.com Inc., is in the business of providing personalized health care information. The Company utilizes AI and clinical practices to improve the healthcare sector and impact current inefficiencies and challenges. It has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). GLM delivers tested clinical information and support to all healthcare professionals as well as provides recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables consistency in the quality of patient support. Its GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. Its wholly owned digital health platform and marketplace is Rocket Doctor.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- June 21st, 2023
- Public Since
- April 19th, 2021
- No. of Employees
- 5
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 75,502,398
- Address
- 8500 Normandale Lake Boulevard, BLOOMINGTON, 55437
- Web
- https://treatment.com/
- Phone
- +1 6127888900
- Auditors
- Davidson & Company LLP
Upcoming Events for TRUE
Similar to TRUE
Aquarius Surgical Technologies
Canadian Securities Exchange
Cannabix Technologies
Canadian Securities Exchange
Diagnostear Technologies
Canadian Securities Exchange
Gemina Laboratories
Canadian Securities Exchange
Imagin Medical
Canadian Securities Exchange
FAQ
As of Today at 23:46 UTC, shares in Treatment.com AI are trading at CA$0.41. This share price information is delayed by 15 minutes.
Shares in Treatment.com AI last closed at CA$0.41 and the price had moved by -62.15% over the past 365 days. In terms of relative price strength the Treatment.com AI share price has underperformed the Toronto Stock Exchange 300 Composite Index by -68.24% over the past year.
There is no consensus recommendation for this security.
Find out moreTreatment.com AI does not currently pay a dividend.
Treatment.com AI does not currently pay a dividend.
Treatment.com AI does not currently pay a dividend.
To buy shares in Treatment.com AI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.41, shares in Treatment.com AI had a market capitalisation of CA$30.58m.
Here are the trading details for Treatment.com AI:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: TRUE
Based on an overall assessment of its quality, value and momentum Treatment.com AI is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Treatment.com AI. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -45.92%.
As of the last closing price of CA$0.41, shares in Treatment.com AI were trading -22.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Treatment.com AI PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Treatment.com AI's directors